Compare · SYK vs TMCI
SYK vs TMCI
Side-by-side comparison of Stryker Corporation (SYK) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYK and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 405.4x TMCI ($312.8M).
- Over the past year, SYK is down 16.2% and TMCI is down 37.5% - SYK leads by 21.3 points.
- SYK has been more active in the news (9 items in the past 4 weeks vs 8 for TMCI).
- SYK has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- Stryker Corporation
- Treace Medical Concepts Inc.
- Price
- $330.60+0.00%
- $4.66-2.82%
- Market cap
- $126.81B
- $312.8M
- 1M return
- -4.61%
- +16.21%
- 1Y return
- -16.23%
- -37.49%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 19
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation
Latest TMCI
- Chief Executive Officer Treace John T. bought $246,654 worth of shares (55,944 units at $4.41), increasing direct ownership by 0.76% to 7,404,383 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.
- Chief Innovation Officer Scanlan Sean F. covered exercise/tax liability with 9,814 shares, decreasing direct ownership by 1% to 679,863 units (SEC Form 4)
- Chief Financial Officer Hair Mark covered exercise/tax liability with 37,102 shares, decreasing direct ownership by 4% to 914,900 units (SEC Form 4)
- Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 16,253 shares, decreasing direct ownership by 2% to 778,683 units (SEC Form 4)
- SEC Form 10-Q filed by Treace Medical Concepts Inc.
- Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Treace Medical Concepts Reports Second Quarter 2026 Financial Results
- Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
- Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System